Zymeworks (ZYME) Insider Trading & Ownership $13.05 +0.33 (+2.59%) Closing price 03/24/2025 04:00 PM EasternExtended Trading$13.18 +0.13 (+0.96%) As of 03/24/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock Zymeworks (NYSE:ZYME) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage1.92%Number OfInsiders Buying(Last 12 Months)15Amount OfInsider Buying(Last 12 Months)$20.03 MNumber OfInsiders Selling(Last 12 Months)3Amount OfInsider Selling(Last 12 Months)$1.34 M Get ZYME Insider Trade Alerts Want to know when executives and insiders are buying or selling Zymeworks stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ZYME Insider Buying and Selling by Quarter Remove Ads Zymeworks Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails3/24/2025Ecor1 Capital, LlcDirectorBuy22,689$13.08$296,772.12 3/21/2025Ecor1 Capital, LlcDirectorBuy31,033$12.78$396,601.74 3/19/2025Ecor1 Capital, LlcDirectorBuy58,306$12.64$736,987.84 3/17/2025Ecor1 Capital, LlcDirectorBuy56,277$12.23$688,267.71 3/13/2025Ecor1 Capital, LlcDirectorBuy468,356$12.48$5,845,082.88 3/11/2025Ecor1 Capital, LlcDirectorBuy320,690$11.49$3,684,728.10 1/17/2025Ecor1 Capital, LlcDirectorBuy19,748$13.87$273,904.76 1/15/2025Ecor1 Capital, LlcDirectorBuy39,029$14.01$546,796.29 1/13/2025Ecor1 Capital, LlcDirectorBuy74,125$13.39$992,533.75 1/10/2025Ecor1 Capital, LlcDirectorBuy204,098$13.13$2,679,806.74 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 1/8/2025Ecor1 Capital, LlcDirectorBuy21,021$14.07$295,765.47 1/6/2025Jeffrey T L SmithEVPSell11,110$14.92$165,761.20 1/6/2025Kenneth GalbraithCEOSell57,291$14.92$854,781.72 1/6/2025Paul Andrew MooreInsiderSell21,200$14.92$316,304.00 1/2/2025Ecor1 Capital, LlcDirectorBuy157,880$14.78$2,333,466.40 12/30/2024Ecor1 Capital, LlcDirectorBuy58,988$14.47$853,556.36 12/26/2024Ecor1 Capital, LlcDirectorBuy16,692$14.38$240,030.96 12/24/2024Ecor1 Capital, LlcDirectorBuy11,958$14.12$168,846.96 (Data available from 1/1/2013 forward) ZYME Insider Trading Activity - Frequently Asked Questions Who is on Zymeworks's Insider Roster? The list of insiders at Zymeworks includes Christopher Astle, Ecor1 Capital, Llc, Jeffrey T L Smith, Kenneth Galbraith, Neil A Klompas, Neil Josephson, and Paul Andrew Moore. Learn more on insiders at ZYME. What percentage of Zymeworks stock is owned by insiders? 1.92% of Zymeworks stock is owned by insiders. Learn more on ZYME's insider holdings. Which Zymeworks insiders have been buying company stock? The following insider purchased ZYME shares in the last 24 months: Ecor1 Capital, Llc ($48,835,148.08). How much insider buying is happening at Zymeworks? Insiders have purchased a total of 5,110,890 ZYME shares in the last 24 months for a total of $48,835,148.08 bought. Which Zymeworks insiders have been selling company stock? The following insiders have sold ZYME shares in the last 24 months: Christopher Astle ($72,740.95), Jeffrey T L Smith ($165,761.20), Kenneth Galbraith ($1,112,611.74), and Paul Andrew Moore ($421,996.58). How much insider selling is happening at Zymeworks? Insiders have sold a total of 130,184 Zymeworks shares in the last 24 months for a total of $1,773,110.47 sold. Zymeworks Key ExecutivesMr. Kenneth H. Galbraith C.A. (Age 61)Chairman of the Board & CEO Compensation: $1.04M1 recent tradesDr. Paul Moore Ph.D. (Age 56)Chief Scientific Officer Compensation: $872.67kMs. Leone D. Patterson M.B.A. (Age 62)CFO, EVP & Chief Business Officer Mr. Mark Hollywood (Age 54)Executive VP and Head of Technical & Manufacturing Operations Mr. Daniel Dex J.D.Ph.D., Senior VP, Corporate Secretary & General CounselDiana PapoveSenior Manager of Corporate CommunicationsDr. Lindsey Foulkes B.Sc.Ph.D., Vice President of Corporate DevelopmentMs. Laura O'ConnorVice President of Human Resources & DEIDr. Jeffrey Smith M.D.Executive VP & Chief Medical OfficerDr. Josemund Menezes MBBSManaging Director of Early-Stage Development for Asia Pacific More Insider Trading Tools from MarketBeat Related Companies IMVT Insider Selling VKTX Insider Selling RYTM Insider Selling SRRK Insider Selling CRNX Insider Selling MRUS Insider Selling PTGX Insider Selling APLS Insider Selling BHVN Insider Selling ACAD Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Grocery Outlet Insider and Institutional Buyers Signal BottomSentinelOne Insider Selling? Why Investors Should Stay Bullish 3 Companies Buying Back Stock—Why It MattersInsider Scoop: 4 Stocks Insiders Are Buying and Selling2 Stocks Insiders Are Buying and 1 They're Selling This page (NYSE:ZYME) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zymeworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ZYME Stock Free ZYME Stock Alerts